Introduction
Inhaled corticosteroids, such as beclomethasone dipropionate (BDP), are well recognized as the most effective antiinflammatory drugs currently available for the treatment of chronic asthma. Research to obtain effective and welltolerated asthma therapies has led to improvements in the delivery systems and formulations of inhaled corticosteroids and to the development of new steroid agents.
This article outlines the history of inhaled steroids from early studies with BDP to the recent advances in inhaled corticosteroid therapy. It then goes on to examine the relative clinical effectiveness of the new and improved formulation of BDP, hydrofluoroalkane-134a (HFA)-BDP extrafine aerosol, with the new steroid, fluticasone propionate (FP).
Development of inhaled steroid therapy
The introduction of inhaled beclomethasone dipropionate nearly 30 years ago (1, 2) radically altered the management of asthma. Prior to the 197Os, patients with asthma were frequently prescribed oral steroids and suffered the predictable systemic side-effects.
After an initial unfavourable clinical trial in Edinburgh, the development of inhaled BDP nearly ceased. Subsequent trials, however, showed that BDP was effective. In these early studies, the efficacy of an inhaled steroid was expressed in terms of the facility in chronic steroiddependent asthmatics to allow reduction of oral steroid therapy. BDP at a dose of 400 pg day-' produced uniform results in patients with chronic asthma, showing an oral steroid sparing effect equivalent to between 5-lOmgday-' of prednisolone (Table 1) . A fuller description of the detail of this early work is available in a comprehensive review by Mygind and Clark (3) .
increase in the diagnosis of the disease and a general increase in inhaled steroid usage. There have also been important advances in delivery systems and in formulations, for example, the new extrafine aerosol preparation of BDP in which BDP is present in a solution of HFA propellant (I-IFA-BDP extrafine aerosol; QVARTM, 3M Pharmaceuticals, St Paul, MN, U.S.A.). This has proved to be a major improvement in the formulation of BDP, resulting in the need for approximately half the dose of the previous, conventional chlorofluorocarbon (CFC) formulation to achieve similar improvements in asthma symptoms (4) (5) (6) (7) .
While larger doses of BDP may be needed for the treatment of more severe asthma, systemic side-effects may become evident at doses of above lOOOpgday-' (8) . Concern about the long-term side-effects of inhaled corticosteroids has led physicians to a strategy of combining a modest dose of an inhaled corticosteroid with bther drugs, such as long-acting bronchodilators. In adults, the maximum recommended daily dose of HFA-BDP extrafine aerosol is 800 fig day-' (9) .
'_ Improvements in the steroid molecule have taken longer to emerge than changes in BDP formulations and delivery systems. FP was introduced in the early 199Os, particularly for patients requiring high doses of conventional CFC-BDP. It is one of the most potent inhaled steroids currently available (10) and has more potent ,antiinflammatory effects in vitro (11) and in vivo (12) than BDP. Fluticasone propionate is more lipophilic than BDP and has a longer tissue half-life than beclomethasone-l7-monopropionate, the active m&abolite of BDP (10) . These properties suggested that fluticasone propionate would prove to be a major therapeutic advance in asthma therapy. The characteristic of having effectively no absorption by mouth was predicted to lead to fewer systemic sideeffects.
In a meta-analysis of clinical trials in patients with asthma of all severities, the efficacy of FP in the treatment of asthma was shown, perhaps disappointingly, to be only equivalent to twice the dose of conventional CFC-BDP throughout the dose range (400-2000 pgday-') (13) . In an earlier study of adults with severe asthma, lOOOpgday-' FP. was shown to be as effective as 2000pgday-' CFC-BDP (14) . More recently, a nebulized preparation of FP given at a dose of 2OOOpg twice daily has been reported to only have an oral steroid effect equivalent to 4.4 mg day-* prednisolone (15). HFA-BDP extrafine aerosol compared with fluticasone propionate HFA-BDP extrafine aerosol has been shown to be as effective as twice the dose of conventional CFC-BDP in the treatment of moderate asthma. This therapeutic ratio is likely to be due to the greatly improved deposition of HFA-BDP extrafine aerosol into the airways of the lung compared with CFC-BDP (16). This improvement probably results from the difference in particle size and dynamics between the two formulations: HFA-BDP has a smaller particle size than CFC-BDP (16) and a lower velocity spray force. (17) . As a result, a smaller fraction of the total dose of HFA-BDP extrafine aerosol is deposited in the larynx and upper respiratory tract compared with conventional CFC-BDP (16) and therefore less drug is swallowed. Theoretically, this should result in fewer adverse effects in tissues outside the lung. In contrast to HFA-BDP, fluticasone propionate has been reported to achieve an in vitro lung deposition of only 20% in a mechanical lung model, with the remainder of the dose being deposited in the oropharynx and larynx ( Fig. 1 ) (18) . The oral systemic bioavailability of FP is very low and there is a high first-pass metabolism (19) so the incidence of systemic side-effects caused by swallowed drug should be minimal. The local steroid side-effects in the larynx are still important. Although dysphonia is a well-recognized complication of inhaled CFC-BDP therapy (20) it appears to be more common with FP than with CFC-BDP, possibly because FP has greater glucocorticoid receptor potency. Overall, dysphonia has been observed in 2% of adults on FP compared to 1% on CFC-BDP (21) . In another study following the use of a higher (1500 pg day-') dose of FP for one year, dysphonia occurred in 6% of adults (22) . Recently, the more serious adverse effect of fungal colonisation of the larynx (laryngeal aspergillosis) has been described when 2000 pgday-' FP was administered for 3 years (23). Clinical studies of HFAbeclomethasone dipropionate extrafine aerosol vs. fluticasone propionate On the basis that HFA-BDP extrafine aerosol has been shown to have approximately 2-2.6 times the comparative dose ratio of conventional CFC-BDP (6) it could be predicted that HFA-BDP extrafine aerosol and FP would prove to be equipotent in the control of asthma. The objective of two recent studies, which directly compared HFA-BDP extrafine aerosol with FP in chronic asthma, was to confirm this predicted equivalence in the clinical setting (24, 25) (Table 2 ).
In the first of these studies (24) we compared 400 pg day-' HFA-BDP with 400pgday-' CFC-FP in adults with asthma that was not adequately controlled on previous inhaled corticosteroid therapy of 200-500 pg day-' CFC-BDP or equivalent. (The most common dose of CFC-BDP used in general practice for the treatment of moderate asthma is 400pgday-'.) This was a randomized, double-blind, double-dummy, parallel-group study conducted in the U.K. and Ireland predominantly in patients from general practice ( Table 2) . Following a 5-9 day run-in period to assess signs and symptoms of asthma, -patients were randomized to 400 pg day-' HFA-BDP (n=88) or 400pgday-' FP (n=84) for 6 weeks. The groups were well matched with no significant differences between them, including the prestudy doses of inhaled corticosteroid. Mean change from baseline in morning (AM) peak expiratory flow (PEF) at week 6 was the primary efficacy variable. AM PEF in both the HFA-BDP extrafine aerosol and FP groups improved significantly compared with baseline values and there was no significant difference between the two groups (Fig. 2) . At weeks 5-6, the mean change from baseline in AM PEF was 19.0 lmin-' for HFA-BDP extrafine aerosol and 30.5 lmin-' for FP and the two groups were shown to be equivalent [90% confidence interval (CI) was -22.47 to -0.59; P=O.O22]. No difference between the two groups was observed when looking at mean percentage change from baselinein FEVl (2.51% and 5.39% for HFA-BDP extrafine aerosol and FP, respectively; P=O.381). Both groups showed similar improvements in symptoms of asthma, such as wheeze, cough, breathlessness, chest tightness and sleep disturbance. Both inhaled steroids led to a decrease in daily p-agonist usage with no differences between treatments. Using the Asthma Quality of Life Questionnaire (26) , no differences between HFA-BDP extrafine aerosol and FP were seen overall or for each of the four domains (Fig. 3) . Thus, 400pgday-' HFA-BDP extrafine aerosol was shown to be equivalent to 400 pg day-' FP. In addition, patients changing from 200-500pgday-' CFC-BDP (or equivalent) to approximately the same dose of HFA-BDP extrafine aerosol experienced improved asthma control. In the second study (25) , Wettengel ef al. compared the efficacy and safety of HFA-BDP extrafine aerosol and HFA-FP at higher doses. This multicentre study (conducted in France, Belgium, Germany and The Netherlands) was similar in design to the low-dose study described above, although it was an open-label comparison using HFA-BDP extrafine aerosol (800pgday-') and the new HFA formulation of FP (lOOOpgday-') and for a slightly longer previous therapy of 500-IOOOpgday-' CFC-BDP, or equivalent, prior to randomization. Patients received either 800 pg day-' HFA-BDP (n=lOl) or lOOOpgday-' HFA-FP (n=97) for 8 weeks. The two groups were well matched. At week 8, mean AM PEF (the primary efficacy variable) had markedly improved from baseline in both groups; mean change from baseline at week 8 was 29.59 1 min-' for HFA-BDP and 17.13 1 min-' HFA-FP (a difference of + 12.46lmin;-' 90% CI -0.02, 24.91) (Fig. 4) . This demonstrated that both groups had the capacity to show improvement in pulmonary function. However, as there appeared to be a greater than anticipated difference between the two treatment groups, a further analysis using the per-protocol population was carried out in order to test for any clinical difference between them. This population is a subset of the ITT population and comprises all those patients who had no major protocol violations, were compliant with the study medication and completed a study diary card.
In the per-protocol population (n=121) the mean change from baseline in AM PEF at week 8 was significantly greater in the QVAR group compared with the HFA-FP group (P<O.Ol). At week 8, the mean change in AM PEF was 34.84 I min-' in the QVAR group and 20.63 1 min-' in the HFA FP group, with a difference of 14.21 I min-' (90% CI; 2.66, 31.10) (Fig 5) . Similarly, FEVl had improved from baseline at week 8 and there was no difference between treatments in mean change from baseline for this parameter. In addition, there were no statistically significant differences between the groups in the mean change from baseline in percentage of days without wheeze, cough, shortness of breath or chest tightness, or nights without sleep disturbance at weeks 3 and 8. However, at week 3, the mean (SE) change from baseline in percentage of days free from daily asthma symptoms was significantly greater in the HFA-BDP group compared with the HFA-FP group [18.32% (3.4%) vs. 6.84% (2.6%); P=O.O3]. This trend was maintained at week 8, although the difference was no longer significant [24.32% symptoms, and sleep disturbance) in both groups and the difference between treatments was not statistically significant (Fig. 6 ). In addition, there was a similar reduction in bronchodilator usage in both groups; the difference between treatments was not significant. Thus, 800 pg day-' HFA-BDP extrafine aerosol provides equivalent asthma control to lOOOpgday-' HFA-FP in patients with moderate-to-severe symptomatic asthma.
In these two relatively short-term studies, the incidence of individual treatment-related adverse events was similarly low for both HFA-BDP extrafine aerosol and FP (Table 3) . For HFA-BDP, the most commonly reported treatmentrelated adverse event in both studies was oropharyngeal fungal infection, reported by 2.3% of patients in study 1 and 4.0% of patients in study 2. For CFC-FP (study 1) inhalation site sensation (2.4%) and cough (2.4%) were the most commonly reported treatment-related adverse events. For HFA-FP (study 2), fungal infection, inhalation site sensation and dysphonia were the most common, each one occurring in 3.1% of patients.
Conclusion
In conclusion, for patients with inadequately controlled asthma, a change from previous inhaled corticosteroid therapy to HFA-beclomethasone dipropionate extrafine aerosol or fluticasone propionate may result in an improvement in asthma control. Low doses (400 pg day-') of FP and HFA-BDP extrafine aerosol appear to be equally effective. In addition, at higher doses, HFA-BDP extrafine aerosol (800pgday-') appears to be as effective as HFA-FP (1000 pgday-'). The choice between these two inhaled steroids should be based on factors other than efficacy in 
